Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: The efficacy of recombinant human soluble thrombomodulin (rhsTM) treatment for acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis

Fig. 2

3-month all-cause mortality. A total of three studies reported 3-month all-cause mortality using univariate analysis, which included 143 subjects. A total of 25 out of 75 patients (33.3%) in rhsTM treatment group died within 3 months while 46 out of 68 patients (67.6%) in control group died within the same period of time. A pooled analysis of three studies demonstrated that 3-month all-cause mortality was significantly better in rhsTM treatment group than control group with an RR of 0.50 (95% CI: 0.35–0.72) with no heterogeneity (chi2 = 0.12, df = 2, p = 0.94, I2 = 0)

Back to article page